Clinical Laboratory Improvement Advisory Committee: Notice of Charter Renewal, 11670-11671 [E6-3261]
Download as PDF
<![CDATA[
11670
Federal Register / Vol. 71, No. 45 / Wednesday, March 8, 2006 / Notices
dollar amount of the total costs of the
project or program that will be financed
by non-governmental sources.
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
3. Reporting Requirements
Agency for Healthcare Research and
Quality
The applicant must provide HHS with
an original, plus two hard copies, as
well as an electronic copy of the
following reports in English:
1. A quarterly progress report, due no
less than 30 days after the end of each
quarter of the budget period. The
progress report for the third quarter of
the year will serve as the non-competing
continuation application. The quarterly
progress report must contain the
following elements:
a. Activities and Objectives for the
Current Budget Period;
b. Financial Progress for the Current
Budget Period;
c. Proposed Activity Objectives for the
New Budget Period;
d. Budget;
e. Measures of Effectiveness; and
f. Additional Requested Information.
2. An annual progress report, due 90
days after the end of the budget period,
which must contain a detailed summary
of the elements required in the quarterly
progress report;
3. Final performance reports, due no
more than 90 days after the end of the
project period; and
4. A Financial Status Report (FSR)
SF–269 is due 90 days after the close of
each 12-month budget period.
Recipients must mail the reports to
the Grants Management Specialist listed
in the ‘‘Agency Contacts’’ section of this
announcement.
VII. Agency Contacts
erjones on PROD1PC68 with NOTICES
For program technical assistance,
contact: Lily O. Engstrom, Senior Policy
Advisor to the Assistant Secretary for
Public Health Emergency Preparedness,
Office of Public Health Emergency
Preparedness, OS, HHS, Telephone:
202.205.4727, E-mail:
lily.engstrom@hhs.gov.
For financial, grants management, or
budget assistance, contact: Grants
Management Specialist, Office of Grants
Management, Office of Public Health
and Science, 11101 Wootten Parkway,
Suite 550, Rockville, MD 20857,
Telephone: (240) 453–8822, E-mail
Address: kcampbell@osophs.dhhs.gov.
Dated: March 2, 2006.
Stewart Simonson,
Assistant Secretary for Public Health
Emergency Preparedness, Department of
Health and Human Services.
[FR Doc. E6–3251 Filed 3–7–06; 8:45 am]
BILLING CODE 4150–37–P
VerDate Aug<31>2005
15:53 Mar 07, 2006
Jkt 208001
Meeting of the National Advisory
Council for Healthcare Research and
Quality
Agency for Healthcare Research
and Quality (AHRQ), HHS.
ACTION: Notice of public meeting.
AGENCY:
SUMMARY: In accordance with section
10(a) of the Federal Advisory Committee
Act, this notice announces a meeting of
the National Advisory Council for
Healthcare Research and Quality.
DATES: The meeting will be held on
Friday, April 7, 2006, from 8:30 a.m. to
4 p.m. and is open to the public.
ADDRESSES: The meeting will be held in
Room 800, the Department of Health
and Human Services, Hubert H.
Humphrey Building, 200 Independence
Avenue, SW., Washington, DC 20201.
FOR FURTHER INFORMATION CONTACT:
Deborah Queenan, Coordinator of the
Advisory Council, at the Agency for
Healthcare Research and Quality, 540
Gaither Road, Rockville, Maryland,
20850, (301) 427–1330. For press-related
information, please contact Karen
Migdail at (301) 427–1855.
If sign language interpretation or other
reasonable accommodation for a
disability is needed, please contact Mr.
Donald L. Inniss, Director, Office of
Equal Employment Opportunity
Program, Program Support Center, on
(301) 443–1144 no later than March 24,
2006. Agenda, roster, and minutes from
previous council meetings are available
from Ms. Bonnie Campbell, Committee
Management Officer, Agency for
Healthcare Quality and Research, 540
Gaither Road, Rockville, Maryland,
20850. Ms. Campbell’s phone number is
(301) 427–1554.
SUPPLEMENTARY INFORMATION:
I. Purpose
Section 921 of the Public Health
Service Act (42 U.S.C. 299c) established
the National Advisory Council for
Healthcare Research and Quality. In
accordance with its statutory mandate,
the Council is to advise the Secretary of
the Department of Health and Human
Services and the Director, Agency for
Healthcare Research and Quality
(AHRQ), on matters related to actions of
the Agency to enhance the quality,
improve the outcomes, reduce the costs
of health care services, improve access
to such services through scientific
research, and to promote improvements
in clinical practice and in the
PO 00000
Frm 00098
Fmt 4703
Sfmt 4703
organization, financing, and delivery of
health care services.
The Council is composed of members
of the public appointed by the
Secretary, and Federal ex-officio
members.
II. Agenda
On Friday, April 7, 2006, the meeting
will convene at 8:30 a.m. with the call
to order by the Council Chair. The
agenda will include the Director’s
update on the status of the Agency’s
current research, programs, and
initiatives; a discussion of ambulatory
care safety; and the findings on breast
cancer from AHRQ’s Effective
Healthcare initiative. The official
agenda will be available on AHRQ’s
Web site at https://www.ahrq.gov no later
than March 31, 2006.
The meeting will adjourn at 4 p.m.
Dated: February 27, 2006.
Carolyn M. Clancy,
Director.
[FR Doc. 06–2189 Filed 3–7–06; 8:45 am]
BILLING CODE 4160–90–M
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
Clinical Laboratory Improvement
Advisory Committee: Notice of Charter
Renewal
This gives notice under the Federal
Advisory Committee Act (Pub. L. 92–
463) of October 6, 1972, that the Clinical
Laboratory Improvement Advisory
Committee, Centers for Disease Control
and Prevention, of the Department of
Health and Human Services, has been
renewed for a 2-year period extending
through February 19, 2008.
For further information, contact
Robert Martin, M.D., Executive
Secretary, Centers for Disease Control
and Prevention, Department of Health
and Human Services, 4470 Buford
Highway, M/S G–25, Chamblee, Georgia
30341, telephone 770–488–8295 or fax
7770–488–8282.
The Director, Management and
Analysis and Services Office, has been
delegated the authority to sign Federal
Register notices pertaining to
announcements of meetings and other
committee management activities for
both the Centers for Disease Control and
Prevention and the Agency for Toxic
Substances and Disease Registry.
E:\FR\FM\08MRN1.SGM
08MRN1
Federal Register / Vol. 71, No. 45 / Wednesday, March 8, 2006 / Notices
Dated: March 2, 2006.
Alvin Hall,
Director, Management Analysis and Services
Office, Centers for Disease Control and
Prevention.
[FR Doc. E6–3261 Filed 3–7–06; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
Government-Owned Inventions;
Availability for Licensing and
Cooperative Research and
Development Agreements (CRADAs)
AGENCY: Centers for Disease Control and
Prevention Technology Transfer Office;
Department of Health and Human
Services.
ACTION:
Notice.
SUMMARY: The invention named in this
notice is owned by agencies of the
United States Government and is
available for licensing in the United
States (U.S.) in accordance with 35
U.S.C. 207, and is available for
cooperative research and development
agreements (CRADAs) in accordance
with 15 U.S.C. 3710a, to achieve
expeditious commercialization of
results of federally funded research and
development. A provisional patent
application has been filed. A Patent
Cooperation Treaty (PCT) application
and national stage foreign patent
applications claiming priority to the
Patent Cooperation Treaty (PCT)
application are expected to be filed
within the appropriate deadlines to
extend market coverage for U.S.
companies and may also be available for
licensing.
Licensing and CRADA
information, and information related to
the technology listed below, may be
obtained by writing to Suzanne Seavello
Shope, J.D., Technology Licensing and
Marketing Scientist, Technology
Transfer Office, Centers for Disease
Control and Prevention (CDC), Mailstop
K–79, 4770 Buford Highway, Atlanta,
GA 30341, telephone (770)488–8613;
facsimile (770)488–8615; or e-mail
sshope@cdc.gov. A signed Confidential
Disclosure Agreement (available under
Forms at https://www.cdc.gov/tto) will be
required to receive copies of
unpublished patent applications and
other information.
erjones on PROD1PC68 with NOTICES
ADDRESSES:
VerDate Aug<31>2005
15:53 Mar 07, 2006
Jkt 208001
Diagnostics
Immunoassay for Diagnosis of
Orthopoxvirus Infection
A CDC-developed immunoassay may
be used for the diagnosis of infection
with Orthopoxviruses (e.g. Monkeypox,
Variola) by detection of acute phase
immune responses that correlate to
recent infection. With recent recognition
of Orthopox viruses as emerging
infectious agents with zoonotic
transmission capabilities as well as
select agents for bioterrorism, assays for
the detection or diagnosis of infections
are sought. This assay provides a rapid
and simple method for detection of
infection with these viruses related to
zoonotic transmission or bioterrorism
events involving such viruses.
Use of the assay produced high levels
of sensitivity during the 2003
Monkeypox outbreak in North America
when compared to PCR.
Commercialization of the ELISA test
may provide a standard screening tool
for diagnosis of Orthopoxvirus as well
as a surveillance tool for exposure.
The immunoassay may also be useful
at the state level for BT surveillance
including an opportunity for use in
reference labs. Reagents used in the
assay are available through CDC
laboratories and for commercial
development of the assay. Further
refinement of the assay may result in the
development of additional reagents for
incorporation into the assay.
Inventors: Kevin L. Karem, Inger K.
Damon and Joanne L. Patton.
CDC Ref. #: I–014–04.
James D. Seligman,
Chief Information Officer, Centers for Disease
Control and Prevention.
[FR Doc. E6–3267 Filed 3–7–06; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
Government-Owned Inventions;
Availability for Licensing and
Cooperative Research and
Development Agreements (CRADAs)
AGENCY: Centers for Disease Control and
Prevention, Technology Transfer Office,
Department of Health and Human
Services.
ACTION: Notice.
SUMMARY: The invention named in this
notice is owned by agencies of the
United States Government and is
available for licensing in the United
PO 00000
Frm 00099
Fmt 4703
Sfmt 4703
11671
States (U.S.) in accordance with 35
U.S.C. 207, and is available for
cooperative research and development
agreements (CRADAs) in accordance
with 15 U.S.C. 3710a, to achieve
expeditious commercialization of
results of federally funded research and
development. A provisional patent
application has been filed. In addition,
the invention is protected by copyright
registration. A Patent Cooperation
Treaty (PCT) application and national
stage foreign patent applications
claiming priority to the Patent
Cooperation Treaty (PCT) application
are expected to be filed within the
appropriate deadlines to extend market
coverage for U.S. companies and may
also be available for licensing.
ADDRESSES: Licensing and CRADA
information, and information related to
the technology listed below, may be
obtained by writing to Suzanne Seavello
Shope, J.D., Technology Licensing and
Marketing Scientist, Technology
Transfer Office, Centers for Disease
Control and Prevention (CDC), Mailstop
K–79, 4770 Buford Highway, Atlanta,
GA 30341, telephone (770)488–8613;
facsimile (770)488–8615; or e-mail
sshope@cdc.gov. A signed Confidential
Disclosure Agreement (available under
Forms at www.cdc.gov/tto) will be
required to receive copies of
unpublished patent applications and
other information.
Software
Computer Software for Automating
Permeation Testing Data Analysis
Data analysis for chemical protective
clothing (CPC) permeation testing
involves a number of equations and
experimental factors. Experimenter bias
and possible calculation errors are
critical issues when determining
permeation parameters. In order to
compare results among different
laboratories and manufacturers, the
normalized breakthrough time is
required since it is not dependent on the
detection limits of the analytical system.
However, calculating the normalized
breakthrough time requires the use of
polynomial curve fitting, polynomial
derivatives, and quadratic equations.
Solving these equations, without a
computer program, would be very
difficult. Therefore, a unique computer
program using Microsoft Visual C++,
referred to as ‘‘Permeation Calculator’’,
has been developed at the National
Institute for Occupational Safety and
Health/National Personal Protective
Technology Laboratory (NIOSH/NPPTL)
to calculate the permeation parameters.
The program imports data and then
calculates the permeation parameters;
E:\FR\FM\08MRN1.SGM
08MRN1
]]>Agencies
[Federal Register Volume 71, Number 45 (Wednesday, March 8, 2006)]
[Notices]
[Pages 11670-11671]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E6-3261]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
Clinical Laboratory Improvement Advisory Committee: Notice of
Charter Renewal
This gives notice under the Federal Advisory Committee Act (Pub. L.
92-463) of October 6, 1972, that the Clinical Laboratory Improvement
Advisory Committee, Centers for Disease Control and Prevention, of the
Department of Health and Human Services, has been renewed for a 2-year
period extending through February 19, 2008.
For further information, contact Robert Martin, M.D., Executive
Secretary, Centers for Disease Control and Prevention, Department of
Health and Human Services, 4470 Buford Highway, M/S G-25, Chamblee,
Georgia 30341, telephone 770-488-8295 or fax 7770-488-8282.
The Director, Management and Analysis and Services Office, has been
delegated the authority to sign Federal Register notices pertaining to
announcements of meetings and other committee management activities for
both the Centers for Disease Control and Prevention and the Agency for
Toxic Substances and Disease Registry.
[[Page 11671]]
Dated: March 2, 2006.
Alvin Hall,
Director, Management Analysis and Services Office, Centers for Disease
Control and Prevention.
[FR Doc. E6-3261 Filed 3-7-06; 8:45 am]
BILLING CODE 4163-18-P
